Posts Tagged ‘drug pricing’

Generic Liraglutide Is Here – Will It Make Any Difference?

June 26, 2024 — One of the four dimensions that sum to a terrible problem of inadequate scale in obesity care is cost. Right now, the list prices for obesity medicines like semaglutide and tirzepatide in the U.S. put them out of reach for all but the wealthy and the well-insured. So will it help that a generic GLP-1 agonist – […]

Can Novo Nordisk Dodge a Senate Subpoena on Pricing?

June 12, 2024 — Senator Bernie Sanders doesn’t want to let this go. Novo Nordisk isn’t eager to cut its thousand-dollar list price for Ozempic. Nor is it eager to face a grilling about this in the Senate. So yesterday, Sanders announced that the Senate Health, Education, Labor, and Pensions committee will vote next Tuesday on a subpoena for […]

Compounded Obesity Medicines Signal Distress

June 1, 2024 — This is a problem of human mistakes. Compounding pharmacies are exploiting the failure of pharmaceutical companies to meet the scale of need for effective obesity medicines. So people with a serious medical need for these medicines face a hideous choice. Suffer without them or take a chance on dodgy compounded products. The fact that this […]

Pressure Builds on GLP-1 Pricing, with More to Come

April 30, 2024 — Last week, the U.S. Senate launched an investigation into the high price of semaglutide, sold as Ozempic and Wegovy by Novo Nordisk. Yes, pressure on GLP-1 pricing is building and you can be confident there’s more to come. Senator Bernie Sanders chairs the Senate Committee on Health, Education, Labor, and Pensions, which is undertaking this […]

Looking for Endoscopy to Save Money on GLP-1s

April 16, 2024 — Right now GLP-1 medicines for obesity carry high list prices that engender great debates about how many billions (hyperbolists will say trillions) of dollars treating obesity will cost healthcare systems. For the uninitiated, it’s quite natural to think of metabolic procedures and obesity medicine in terms of either/or questions. No matter that this is a […]

Anticompetitive Pricing for Diabetes and Obesity Drugs

April 4, 2024 — We have much to learn from a recent crisis of escalating insulin prices. This is the bottom line of a new paper in Diabetes Care. In short, multifaceted public policy action eased that crisis. So it has important implications for issues with anticompetitive pricing of diabetes and obesity medicines broadly. Anticompetitive Pricing Practices Authors Kathryn […]

Will Policy Makers or Market Forces Lower GLP-1 Costs First?

March 28, 2024 — A new economic analysis in JAMA Network Open brings unsurprising news: manufacturing costs for GLP-1 agonists are a tiny fraction of the price for these important medicines. This is always the case for innovative prescription drugs that must recover billions of dollars of development costs in order to be profitable. The response from policy makers […]

Scarcity, Greed, and Drug Pricing in an Election Year

March 10, 2024 — For many of us, it’s just too painful to think about. But a rerun of the 2020 presidential election is coming and drug pricing is likely to be a big talking point for both of the major candidates. President Biden is talking about corporate greed while former President Trump is talking about reviving an executive […]

What Will Be Hot or Not in 2024 for Obesity and Health

January 2, 2024 — The year we just finished saw quite a pivot in the science and policy we cover here. So what will we pivot toward in 2024? What will leave us cold? Here are our best educated guesses for what will be hot or not in 2024 for obesity and health. #1 Hot: Pricing Drug prices will […]

The Top 10 Most Read Posts of 2023 on ConscienHealth

December 21, 2023 — No two ways about it. This has been a big year of milestones in obesity and health. We and many others are still processing what we have witnessed in these past 12 months. But one way to gain perspective is to look at 2023 stats for the posts on ConscienHealth that you, a wise group […]